10X Genomics Inc is a biotechnology company focused on advancing the field of genomics through innovative technologies that enable researchers to explore biological systems at a single-cell level. The company's mission is to empower scientists to unlock the complexities of biology and disease by providing high-resolution genomic analysis tools. 10X Genomics Inc employs a strategy centered on continuous innovation and collaboration with the scientific community, offering a range of products that enhance genomic sequencing, gene expression analysis, and spatial biology. Their operations are driven by a commitment to improving human health through groundbreaking research and discoveries in genomics.

10X GENOMICS INC

10x Genomics, Inc. (NASDAQ: TXG) recently held its Q4 2024 earnings conference call on February 12, 2025, revealing significant insights into the company's financial status. CEO Serge Saxonov reported a challenging quarter, with a 10% decline in fourth-quarter revenues and a 1% drop in total revenues for 2024, amounting to...

10x Genomics Reports Decline in Q4 Revenues Amid NIH Funding Concerns and Projects Modest Growth for 2025

10x Genomics faces a challenging landscape with a 10% decline in Q4 revenues and a net loss of $182.6 million for 2024, largely influenced by NIH funding changes. As the company anticipates modest growth for 2025, can it navigate these financial hurdles while maintaining its innovative edge?